BR112022025623A2 - Agonistas solúveis de receptores de npy2 - Google Patents

Agonistas solúveis de receptores de npy2

Info

Publication number
BR112022025623A2
BR112022025623A2 BR112022025623A BR112022025623A BR112022025623A2 BR 112022025623 A2 BR112022025623 A2 BR 112022025623A2 BR 112022025623 A BR112022025623 A BR 112022025623A BR 112022025623 A BR112022025623 A BR 112022025623A BR 112022025623 A2 BR112022025623 A2 BR 112022025623A2
Authority
BR
Brazil
Prior art keywords
analogues
npy2
receptors
soluble
soluble agonists
Prior art date
Application number
BR112022025623A
Other languages
English (en)
Inventor
Haebel Peter
Brennauer Albert
Peters Stefan
Stahl Madsen Charlotte
Ljungberg Pedersen Søren
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BR112022025623A2 publication Critical patent/BR112022025623A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

BOEHRINGER INGELHEIM INTERNATIONAL GMBH. A presente invenção refere-se a análogos de PYY tendo alanina na posição 4, lisina na posição 7, QRY como a extremidade do terminal-C e um grupo de extensão de meia-vida. Os análogos da invenção são solúveis em torno do pH 6 e 7. A invenção também se refere a composições farmacêuticas compreendendo os referidos análogos de PYY, e ao uso médico dos análogos.
BR112022025623A 2020-08-07 2021-08-05 Agonistas solúveis de receptores de npy2 BR112022025623A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20189966 2020-08-07
PCT/EP2021/071873 WO2022029231A1 (en) 2020-08-07 2021-08-05 Soluble npy2 receptor agonists

Publications (1)

Publication Number Publication Date
BR112022025623A2 true BR112022025623A2 (pt) 2023-03-07

Family

ID=71995807

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025623A BR112022025623A2 (pt) 2020-08-07 2021-08-05 Agonistas solúveis de receptores de npy2

Country Status (19)

Country Link
US (1) US20220041678A1 (pt)
EP (1) EP4192853A1 (pt)
JP (1) JP2023537036A (pt)
KR (1) KR20230045088A (pt)
CN (1) CN116171282A (pt)
AR (1) AR123174A1 (pt)
AU (1) AU2021322137A1 (pt)
BR (1) BR112022025623A2 (pt)
CA (1) CA3185637A1 (pt)
CL (1) CL2023000357A1 (pt)
CO (1) CO2023000637A2 (pt)
CR (1) CR20230074A (pt)
DO (1) DOP2023000010A (pt)
EC (1) ECSP23003649A (pt)
IL (1) IL300239A (pt)
MX (1) MX2023001532A (pt)
PE (1) PE20231566A1 (pt)
TW (1) TW202222335A (pt)
WO (1) WO2022029231A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022210988B9 (en) 2021-01-20 2024-02-22 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
US20240091318A1 (en) 2022-08-18 2024-03-21 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525495A (ja) 2004-02-11 2007-09-06 アミリン・ファーマシューティカルズ，インコーポレイテッド 選択可能な特性を有するハイブリッドポリペプチド
BRPI0518559A2 (pt) 2004-12-13 2008-11-25 Amylin Pharmaceuticals Inc motivos da famÍlia do polipetÍdeo pancreÁtico, polipeptÍdeos e mÉtodos compreendendo os mesmos
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
WO2008152403A1 (en) 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
CN101939022A (zh) 2007-11-14 2011-01-05 安米林药品公司 治疗肥胖以及肥胖相关疾病和病症的方法
WO2010070252A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
UA104605C2 (uk) 2008-12-15 2014-02-25 Зіленд Фарма А/С Аналоги глюкагону
CN102282166B (zh) 2008-12-15 2015-04-01 西兰制药公司 胰高血糖素类似物
KR101593406B1 (ko) 2008-12-15 2016-02-12 질랜드 파마 에이/에스 글루카곤 유사체
PL2454282T3 (pl) 2009-07-13 2015-08-31 Zealand Pharma As Acylowane analogi glukagonu
EP2477643A1 (en) 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
US20130096055A1 (en) 2009-11-13 2013-04-18 Novo Nordisk A/S Long-acting y2 receptor agonists
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
JP6023048B2 (ja) 2010-06-24 2016-11-09 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
PL2718316T3 (pl) 2011-06-10 2020-06-29 Novo Nordisk A/S Polipeptydy
KR20140114845A (ko) 2011-12-23 2014-09-29 질랜드 파마 에이/에스 글루카곤 유사체
KR102184241B1 (ko) 2012-05-03 2020-12-01 질랜드 파마 에이/에스 Ｇｉｐ-ｇｌｐ-1 이원 작용제 화합물 및 방법
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
ES2732291T3 (es) 2013-05-02 2019-11-21 Glaxosmithkline Ip Dev Ltd Péptidos terapéuticos
AR097701A1 (es) 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
EP3057984B1 (en) 2013-10-17 2018-07-11 Zealand Pharma A/S Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
TR201902516T4 (tr) 2013-11-06 2019-03-21 Zealand Pharma As Glukagon-glp-1-gıp üçlü agonist bileşikleri.
MX2016006049A (es) 2013-11-14 2016-08-12 Keybioscience Ag Mimeticos de calcitonina para tratar enfermedades y trastornos.
RS59026B1 (sr) 2013-11-15 2019-08-30 Novo Nordisk As Selektivna pyy jedinjenja i njihova upotreba
JP6769984B2 (ja) 2015-03-18 2020-10-14 ジーランド ファーマ アクティーゼルスカブ アミリン類似体
MX2017012864A (es) 2015-04-16 2018-06-12 Zealand Pharma As Analogo acilado del glucagon.
TWI694082B (zh) 2015-06-12 2020-05-21 丹麥商諾佛 儂迪克股份有限公司 選擇性ｐｙｙ化合物及其用途
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
HRP20220995T1 (hr) 2015-12-31 2022-11-11 Hanmi Pharm. Co., Ltd. Trostruki aktivator koji aktivira glukagonski, glp-1 i gip receptore
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
JOP20190097A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها
AR110300A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
AR110301A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
TWI749381B (zh) 2018-11-01 2021-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
JP2023500895A (ja) * 2019-11-11 2023-01-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｎｐｙ２受容体アゴニスト

Also Published As

Publication number Publication date
JP2023537036A (ja) 2023-08-30
AU2021322137A1 (en) 2023-01-19
WO2022029231A1 (en) 2022-02-10
CN116171282A (zh) 2023-05-26
MX2023001532A (es) 2023-03-08
US20220041678A1 (en) 2022-02-10
IL300239A (en) 2023-03-01
EP4192853A1 (en) 2023-06-14
CA3185637A1 (en) 2022-02-10
AR123174A1 (es) 2022-11-02
CO2023000637A2 (es) 2023-01-26
ECSP23003649A (es) 2023-03-31
TW202222335A (zh) 2022-06-16
KR20230045088A (ko) 2023-04-04
DOP2023000010A (es) 2023-02-15
CL2023000357A1 (es) 2023-09-29
CR20230074A (es) 2023-04-19
PE20231566A1 (es) 2023-10-04

Similar Documents

Publication Publication Date Title
BR112022025623A2 (pt) Agonistas solúveis de receptores de npy2
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
BR112016010383A2 (pt) compostos de pyy seletivos e usos dos mesmos
BR0212897A (pt) Conjugados de análogos de somatostatina ou bombesina diagnóstica ou terapêutica e usos dos mesmos
ECSP22037660A (es) Agonistas del receptor npy2
JP2020508970A5 (pt)
AR120079A1 (es) Liberación selectiva de fármacos de conjugados internalizados de compuestos biológicamente activos
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
PE20210654A1 (es) Formulaciones de composiciones de vacuna contra el virus del dengue
BR112023018842A2 (pt) Liberação de fármaco seletiva de conjugados
BR112022006297A2 (pt) Agonistas de receptor de npy2
AR117707A1 (es) Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf
BR0206407A (pt) Composto, composição farmacêutica, e, utilização de um composto
CO2023002650A2 (es) Formas farmacéuticas sólidas de palbociclib
BR112023001428A2 (pt) Ligantes à base de peptídios
BR112022012739A2 (pt) Proteínas de andaime e nanoconjugados terapêuticos à base de nidogênio
BR112022003751A2 (pt) Análogos de hemoglobina reticulada com tiosuccinila e métodos de uso e preparação dos mesmos
AR014884A1 (es) Uso de un conjugado de angiotensina inmunogenico y composicion farmaceutica
AR062674A1 (es) Formulacion acuosa que comprende un agente antitumoral
CO2021009028A2 (es) Composiciones para uñas con propiedades antifúngicas
CL2022002932A1 (es) Composiciones y métodos para suministrar agentes farmacéuticamente activos
BR112023002077A2 (pt) Composto e seu uso, composição e formulação farmacêutica
BR112022006313A2 (pt) Formulação de suspensão pediátrica
BR112022000760A2 (pt) Composições, método para preparar um conjugado de longa duração de um polipeptídeo fisiologicamente ativo e conjugado de fármaco de longa duração
UY38249A (es) Productos conjugados que comprenden un agonista del receptor triple de glp-1/glucagón/gip, un conector y ácido hialurónico